Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026
Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026
Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026
Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026
Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Company Deals

Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics

Fineline Cube Dec 15, 2022

Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program

Fineline Cube Dec 14, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...

Company Digital Drug

111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China

Fineline Cube Dec 14, 2022

China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...

Company Deals

Biosion and ImmunoGen Collaborate on Cancer ADCs

Fineline Cube Dec 14, 2022

China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...

Company Deals

Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics

Fineline Cube Dec 14, 2022

UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...

Company Deals

Henlius Biotech Partners with Medilink for Global ADC Development

Fineline Cube Dec 14, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...

Company Drug

Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study

Fineline Cube Dec 14, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...

Company Medical Device

Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study

Fineline Cube Dec 14, 2022

China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...

Policy / Regulatory

China’s COVID-19 Vaccination Second Booster Shot Plan Released

Fineline Cube Dec 14, 2022

The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...

Company Drug

ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval

Fineline Cube Dec 14, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...

Company Drug

Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial

Fineline Cube Dec 14, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...

Company Drug

Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting

Fineline Cube Dec 14, 2022

China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...

Company Medical Device

Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation

Fineline Cube Dec 14, 2022

Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...

Policy / Regulatory

Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues

Fineline Cube Dec 13, 2022

The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...

Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Posts pagination

1 … 584 585 586 … 663

Recent updates

  • Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties
  • Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304
  • CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer
  • AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions
  • CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.